EP Patent

EP3651775A1 — Methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression

Assigned to Alnylam Pharmaceuticals Inc · Expires 2020-05-20 · 6y expired

What this patent protects

The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

USPTO Abstract

The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Drugs covered by this patent

Patent Metadata

Patent number
EP3651775A1
Jurisdiction
EP
Classification
—
Expires
2020-05-20
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.